

Savina Sn Nodari

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5578254/savina-sn-nodari-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers

5,305
citations

33
h-index

72
g-index

140
ext. papers

6,313
ext. citations

4.2
avg, IF

5.3
L-index

#	Paper	IF	Citations
106	Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan.. <i>ESC Heart Failure</i> , 2022 ,	3.7	1
105	Impact of 2020 SARS-CoV-2 outbreak on telemedicine management of cardiovascular disease in Italy. <i>Internal and Emergency Medicine</i> , 2021 , 16, 1191-1196	3.7	4
104	Effects of the COVID-19 pandemic on the formation of fellows in training in cardiology. <i>Journal of Cardiovascular Medicine</i> , 2021 , 22, 711-715	1.9	1
103	Quick response code applications in medical and cardiology settings: a systematic scoping review. <i>European Heart Journal Digital Health</i> , 2021 , 2, 336-341	2.3	0
102	New Targets in Heart Failure Drug Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 665797	5.4	1
101	Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. <i>Heart Failure Reviews</i> , 2021 , 1	5	2
100	Vericiguat for Heart Failure with Reduced Ejection Fraction. <i>Current Cardiology Reports</i> , 2021 , 23, 144	4.2	6
99	Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. <i>European Heart Journal</i> , 2020 , 41, 1821-1829	9.5	299
98	The oldest Society of Cardiology in Italy meets the ESC. <i>European Heart Journal</i> , 2020 , 41, 2055-2058	9.5	1
97	Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. <i>Heart Failure Reviews</i> , 2020 , 1	5	1
96	Comprehensive heart failure assessment: A challenge to modify the course of heart failure. Author's reply. <i>European Journal of Internal Medicine</i> , 2020 , 74, 125-126	3.9	0
95	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. <i>Journal of Cardiac Failure</i> , 2020 , 26, 429-437	3.3	19
94	Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial. <i>American Heart Journal</i> , 2020 , 224, 129-137	4.9	4
93	Genetic test for Mendelian fatigue and muscle weakness syndromes. <i>Acta Biomedica</i> , 2020 , 91, e20200013.2		1
92	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. <i>European Heart Journal</i> , 2020 , 41, 2083-2088	9.5	437
91	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. <i>European Journal of Internal Medicine</i> , 2020 , 71, 23-31	3.9	17
90	An expression of concern on research during the Covid-19 pandemic. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 838-839	1.9	5

89	Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial. <i>Clinical Pharmacology in Drug Development</i> , 2019 , 8, 942-951	2.3	10
88	Redefining biomarkers in heart failure. <i>Heart Failure Reviews</i> , 2018 , 23, 237-253	5	17
87	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 281-291	12.3	17
86	Questioning the Associations of Ω 3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. <i>JAMA Cardiology</i> , 2018 , 3, 781	16.2	1
85	A new educational program in heart failure drug development: the Brescia international master program. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19, 411-421	1.9	7
84	Right heart dysfunction: from pathophysiologic insights to therapeutic options: a translational overview. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19, 613-623	1.9	4
83	Mediterranean diet impact on cardiovascular diseases: a narrative review. <i>Journal of Cardiovascular Medicine</i> , 2017 , 18, 925-935	1.9	46
82	Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. <i>Annals of Hematology</i> , 2017 , 96, 549-558	3	32
81	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 440-451	2.9	33
80	Preventing antineoplastic drug-related cardiomyopathy: old and new therapeutic strategies. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17 Suppl 1, S64-75	1.9	18
79	Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold. <i>American Journal of Cardiology</i> , 2016 , 117, 1231-5	3	28
78	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016 , 117, 340-6	3	12
77	Role of biomarkers in monitoring antineoplastic cardiotoxicity. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17 Suppl 1, S27-34	1.9	17
76	Management of heart failure in the new era: the role of scores. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17, 569-80	1.9	8
75	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , 2016 , 18, 54-65	12.3	57
74	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 799-809	2.5	10
73	Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. <i>Nutrition</i> , 2015 , 31, 72-8	4.8	47
72	Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). <i>American Journal of Cardiology</i> , 2015 , 115, 790-6 ³		28

71	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1123-1133	15.1	1160
70	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , 2014 , 2, 97-112	7.9	213
69	Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 401-8	7.6	27
68	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , 2014 , 19, 135-52	5	39
67	Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure. <i>Clinical Medicine Insights: Cardiology</i> , 2014 , 8, 39-44	3.2	34
66	Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. <i>American Journal of the Medical Sciences</i> , 2014 , 347, 271-6	2.2	17
65	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013 , 18, 107-22	5	39
64	Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. <i>International Journal of Cardiology</i> , 2013 , 163, 206-11	3.2	85
63	Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2013 , 111, 574-81	3	40
62	Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2013 , 112, 1763-9	3	6
61	Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 1401-11	12.3	100
60	Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 194-202	12.3	126
59	The left ventricle as a mechanical engine: from Leonardo da Vinci to the echocardiographic assessment of peak power output-to-left ventricular mass. <i>Journal of Cardiovascular Medicine</i> , 2013 , 14, 214-20	1.9	4
58	Six-year prognosis of diabetic patients with coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2012 , 42, 376-83	4.6	12
57	Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 750-8	7.6	62
56	Omega-3 Polyunsaturated Fatty Acid Supplementation: Mechanism and Current Evidence in Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2012 , 5, 718	0.8	6
55	Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 870-9	15.1	153
54	Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2011 , 12, 76-84	1.9	45

53	Acute heart failure syndromes: assessment and reconstructing the heart. <i>Journal of Cardiovascular Medicine</i> , 2011 , 12, 258-63	1.9	4
52	Current treatment in acute and chronic cardio-renal syndrome. <i>Heart Failure Reviews</i> , 2011 , 16, 583-94	5	8
51	Effects of supplementation with polyunsaturated fatty acids in patients with heart failure. <i>Internal and Emergency Medicine</i> , 2011 , 6 Suppl 1, 37-44	3.7	9
50	n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. <i>Circulation</i> , 2011 , 124, 1100-6	16.7	94
49	Clinical impact of renal dysfunction in heart failure. <i>Reviews in Cardiovascular Medicine</i> , 2011 , 12, 186-99	3.9	7
48	Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2010 , 3, 51-60	2.5	4
47	Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?. <i>Current Heart Failure Reports</i> , 2010 , 7, 100-9	2.8	12
46	The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. <i>Cardiovascular Drugs and Therapy</i> , 2009 , 23, 5-15	3.9	47
45	Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article "The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy" <i>Cardiovascular Drugs and Therapy</i> , 2009 , 23, 335-336	3.9	
44	High sensitivity C-reactive protein: a predictor for recurrence of atrial fibrillation after successful cardioversion. <i>Internal and Emergency Medicine</i> , 2009 , 4, 309-13	3.7	13
43	Persistence of left superior vena cava, absence of coronary sinus and cerebral ictus. <i>International Journal of Cardiology</i> , 2008 , 126, e39-41	3.2	8
42	Lack of association of coeliac disease with idiopathic and ischaemic dilated cardiomyopathies. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008 , 68, 692-5	2	8
41	Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. <i>European Journal of Heart Failure</i> , 2008 , 10, 188-95	12.3	285
40	CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. <i>Echocardiography</i> , 2008 , 25, 955-60	1.5	19
39	The 6-min walking test early after cardiac surgery. Reference values and the effects of rehabilitation programme. <i>European Journal of Cardio-thoracic Surgery</i> , 2007 , 32, 724-9	3	76
38	The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. <i>European Journal of Heart Failure</i> , 2007 , 9, 776-86	12.3	122
37	Beta-blocker therapy of heart failure: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 289-98	4	2
36	Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. <i>Therapeutics and Clinical Risk Management</i> , 2007 , 3, 569-78	2.9	5

35	The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia. <i>Heart International</i> , 2007 , 3, 12	0.3	3
34	Nitric oxide and cardiovascular risk factors. <i>Heart International</i> , 2007 , 3, 18	0.3	7
33	The study of left ventricular diastolic function by Doppler echocardiography: the essential for the clinician. <i>Heart International</i> , 2007 , 3, 42	0.3	1
32	The Prevention of Sudden Death: New Perspectives 2007 , 205-213		
31	Endocannabinoids and cardiovascular prevention: real progress?. <i>Heart International</i> , 2007 , 3, 27	0.3	
30	Anemia and heart failure: a cause of progression or only a consequence?. <i>Heart International</i> , 2007 , 3, 1	0.3	
29	Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study. <i>European Journal of Heart Failure</i> , 2006 , 8, 131-5	12.3	26
28	Non-compaction of the ventricular myocardium. <i>Heart International</i> , 2006 , 2, 178	0.3	2
27	Improved Graft Patency Rates and Mid-Term Outcome of Diabetic Patients Undergoing Total Arterial Myocardial Revascularization. <i>Heart International</i> , 2006 , 2, 182618680600200	0.3	1
26	Endothelial Damage Due to Air Pollution. <i>Heart International</i> , 2006 , 2, 182618680600200	0.3	
25	Managing heart failure in the very old. <i>Aging Health</i> , 2006 , 2, 253-275		
24	Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report. <i>Journal of Cardiovascular Medicine</i> , 2006 , 7, 182-7	1.9	5
23	Endothelial damage due to air pollution. <i>Heart International</i> , 2006 , 2, 115	0.3	1
22	Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization. <i>Heart International</i> , 2006 , 2, 136	0.3	2
21	Current guidelines in the pharmacological management of chronic heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004 , 5 Suppl 1, S11-6	3	2
20	Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. <i>European Heart Journal</i> , 2004 , 25, 1534-41	9.5	34
19	Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. <i>European Journal of Heart Failure</i> , 2003 , 5, 621-7	12.3	98
18	Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. <i>European Journal of Heart Failure</i> , 2003 , 5, 803-9	12.3	15

17	Prevention and management of chronic heart failure in patients at risk. <i>American Journal of Cardiology</i> , 2003 , 91, 10F-17F	3	17
16	Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 1805-11	15.1	122
15	Off-pump coronary artery bypass surgery technique for total arterial myocardial revascularization: a prospective randomized study. <i>Annals of Thoracic Surgery</i> , 2003 , 76, 778-82; discussion 783	2.7	99
14	Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. <i>American Heart Journal</i> , 2003 , 145, 292-9	4.9	94
13	Is total arterial myocardial revascularization with composite grafts a safe and useful procedure in the elderly?. <i>European Journal of Cardio-thoracic Surgery</i> , 2003 , 23, 657-64; discussion 664	3	18
12	Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery. <i>Circulation</i> , 2003 , 108 Suppl 1, II29-33	16.7	35
11	Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1248-58	15.1	179
10	Beta-blockade in heart failure: selective versus nonselective agents. <i>American Journal of Cardiovascular Drugs</i> , 2001 , 1, 3-14	4	14
9	Selective or nonselective beta-adrenergic blockade in patients with congestive heart failure. <i>Current Cardiology Reports</i> , 2000 , 2, 252-7	4.2	1
8	Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. <i>Circulation</i> , 2000 , 102, 546-51	16.7	282
7	A rationale for the use of beta-blockers as standard treatment for heart failure. <i>American Heart Journal</i> , 2000 , 139, 511-21	4.9	53
6	Beta Blockers in Heart Failure: Issues in Management of Individual Patients. <i>Heart Failure Reviews</i> , 1999 , 4, 65-78	5	2
5	Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 943-50	15.1	100
4	Maximal and Submaximal Exercise Testing in Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32, S36-S45	3.1	4
3	Pharmacological activity of the new calcium antagonist, lacidipine, on isolated preparations. <i>General Pharmacology</i> , 1996 , 27, 1255-9		2
2	Combined invasive and noninvasive study of left ventricular systolic and diastolic function following acute administration of cicloprolol to subjects with normal cardiac function. <i>Cardiovascular Drugs and Therapy</i> , 1992 , 6, 513-7	3.9	
1	Integrated Heart Failure Management in the Patient with Heart Failure Caused by Left Ventricular Systolic Dysfunction1-30		